Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03827772
Other study ID # PGIMER Hepatology
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 2019
Est. completion date December 2019

Study information

Verified date January 2019
Source Postgraduate Institute of Medical Education and Research
Contact Radha K Dhiman, DM
Phone 7087009337
Email rkpsdhiman@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Alcoholic liver disease has become one of the foremost causes of chronic liver disease across the world, and a cause of considerable morbidity and mortality. Alcoholic steatohepatitis is an entity in this broad spectrum, with severe alcoholic hepatitis transitioning to acute on chronic liver failure carrying a one month mortality of as high as 20 to 50%.

The current management guidelines for severe alcoholic hepatitis show benefit with prolonged alcohol abstinence, nutritional support, the use of corticosteroids, pentoxifylline or N-acetyl cysteine (NAC) and early liver transplantation. However, major studies and meta-analyses have demonstrated that these interventions, with the exception of early liver transplantation, do not improve mortality rates to the level of statistical significance. Owing to the high short term mortality associated with severe alcoholic hepatitis, the inadequacy of a treatment that could significantly impact this short term mortality, and the limited applicability of early liver transplantation, a study on newer modalities of treatment is warranted.

The role that human gut microbiota plays in health and disease is receiving considerable attention. Targeting intestinal dysbiosis, a phenomenon found to be intricately linked with the causation of alcoholic hepatitis, could provide insights into novel therapeutic strategies.

Fecal microbiota transplantation is a novel approach that has gained widespread acceptance in in the management of recurrent severe Clostridium difficile infection. It's role is also being studied in other diseases where an association with gut dysbiosis has been found, such as in inflammatory bowel disease and irritable bowel syndrome. The role of FMT has also been studied in liver diseases such as non-alcoholic fatty liver disease (NAFLD), liver cirrhosis and primary sclerosing cholangitis. In this process, a diseased recipient is transferred fecal material containing the microflora of a healthy individual. It limits the colonization of pathogens, inducing colonization resistance, affects microbiota composition in the gut, as well as metabolism in the microbial pathogens. FMT helps alleviate gut dysbiosis and restores gut microbial diversity.

Our aim is to evaluate the role of FMT on short term survival and improvement in scores of prognostic significance (CTP, MELD, MELDNa, mDF) in patients with severe alcoholic hepatitis.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 2019
Est. primary completion date December 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Severe alcoholic hepatitis will be defined as proposed by the American College of Gastroenterology

1. Rapid development or worsening of jaundice and liver-related complications with serum total bilirubin more than 3 milligrams per decilitre.

2. Aspartate aminotransferase and alanine aminotransferase elevated to more than one and half times the upper limit of normal, but less than 400 IU per litre, with AST to ALT ratio over 1.5.

3. Documentation of persistent heavy alcohol use until 8 weeks before onset of symptoms.

4. Alcohol Consumption in female over 40 grams per day for at least 6 months and in males over 60 grams per day for at least 6 months.

5. Maddrey's Discriminant Function Score of more than 32 OR

6. A patient of alcoholic hepatitis who will present with grade 1 or 2 of hepatic encephalopathy.

Exclusion Criteria:

1. Intestinal paralysis, lack of bowel sounds, intestinal perforation.

2. Uncontrolled infections.

3. Uncontrolled upper gastrointestinal bleeding.

4. Grade 3,4 hepatic encephalopathy.

5. Hepatic or extrahepatic malignancy.

6. Maddrey's Discriminant Function (mDF) >90 or MELD>30.

7. Autoimmune hepatitis, Wilson's disease, suspected drug induced liver injury.

8. Patients who are aged >60 years

9. WBC count <1000 cells/mm3

10. Pregnancy or nursing.

11. Human Immunodeficiency Virus (HIV), HBV, HCV infection.

12. Patient's unwillingness to participate in the study.

13. Any other condition which, in the opinion of the investigator, would impede compliance or hinder completion of the study.

Study Design


Intervention

Other:
Fecal Microbiota Transplantation
30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
Standard of care treatment
Nutritional supplementation, supportive management.

Locations

Country Name City State
India Postgraduate Institute of Medical Education and Research Chandigarh

Sponsors (1)

Lead Sponsor Collaborator
Postgraduate Institute of Medical Education and Research

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Survival 3 months
Secondary Improvement in CTP (Child Turcotte Pugh Score) 3 months
Secondary Improvement in MELD score 3 months
Secondary Improvement in MELDNa score 3 months
Secondary Improvement in CLIF SOFA score 3 months
Secondary Improvement in mDF 3 months
Secondary Changes in inflammatory markers (IL1b, IL6, TNF a) pre and post FMT, 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT04106518 - Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
Not yet recruiting NCT06155760 - Role of Extended Low Dose Prednisolone in Achieving Clinical and Biochemical Remission in Steroid Responsive Severe Alcoholic Hepatitis N/A
Completed NCT02808663 - Assessment of the Predictive Value of Fecal Calprotectin for the Outcome of Severe Alcoholic Hepatitis N/A
Completed NCT01820208 - Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis N/A
Withdrawn NCT03087968 - Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124 Early Phase 1
Not yet recruiting NCT02485106 - Rifaximin Use in Severe Alcoholic Hepatitis Phase 3
Completed NCT01801332 - Intensive Enteral Nutrition and Acute Alcoholic Hepatitis N/A
Recruiting NCT04103840 - Invasive Fungal Infections in Severe Alcohol-associated Hepatitis
Active, not recruiting NCT03091010 - A Comparison of Fecal Microbiota Transplantation and Steroid Therapy in Patients With Severe Alcoholic Hepatitis. N/A
Completed NCT02161653 - Metadoxine as a Therapy for Severe Alcoholic Hepatitis Phase 4